The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky BetByJustin Kozak, Founder ShieldJuly 16th 2025Why startups and life sciences companies should approach this booming sector with extreme caution.
M&A in Pharma: Balancing Growth and RiskByJustin Kozak, Founder ShieldFebruary 7th 2025What factors should be considered—and how can both parties benefit long-term?